Challenges and Opportunities in the Discovery of New Therapeutics Targeting the Kynurenine Pathway
Tóm tắt
Từ khóa
Tài liệu tham khảo
1-Methyl-D-tryptophan and docetaxel in treating patients with metastatic solid tumors.http://clinicaltrials.gov/show/NCT01191216(accessed June 17, 2015) .
1-Methyl-D-tryptophan in treating patients with metastatic or refractory solid tumors that cannot be removed by surgery.http://clinicaltrials.gov/show/NCT00567931(accessed June 17, 2015) .
Multiple ongoing clinical trials.https://clinicaltrials.gov/ct2/results?term=indoximod&Search=Search(accessed June 17, 2005) .
Mautino, M.; Kumar, S.; Jaipuri, F.; Waldo, J.; Kesharwani, T.; Zhang, X.Imidazole derivatives as IDO inhibitors. WO2011056652, 2011.
Mautino, M.; Kumar, S.; Waldo, J.; Jaipuri, F.; Kesharwani, T.Fused imidazole derivatives useful as IDO inhibitors. WO2012142237, 2012.
Kumar, S.; Waldo, J.; Jaipuri, F.; Mautino, M.Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization. WO2014159248, 2014.
Newlink Genetics. NLG919, a novel indoleamine-2,3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy.http://newlinkgenetics.com/assets/pdfs/AACR_2013_-_NLG919_and_Indoximod.pdf(accessed June 17, 2015) .
IDO inhibitor in advanced solid tumors.https://clinicaltrials.gov/ct2/show/NCT02048709?term=NLG919&rank=1’(accessed June 17, 2015) .
Combs, A. P.; Zhu, W.; Sparks, R. B.Preparation of N-hydroxyamidinooxadiazoles and related analogs as modulators of indoleamine 2,3-dioxygenase. WO2008058178A1, 2008.
Combs, A. P.; Yue, E. W.; Sparks, R. B.; Zhu, W.; Zhou, J.; Lin, Q.; Weng, L.; Yue, T.Y.; Liu, P.Preparation of 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase. WO2010005958A2, 2010.
Pharmacodynamic assessment of INCB024360, an inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1) in advanced cancer patients.http://www.incyte.com/sites/default/files/ASCO%202012%20-%20INCB024360%20oral%20presentation%20-%20FINAL%20sec.pdf(accessed June 22, 2015) .
Bristol-Myers Squibb and Incyte enter into a clinical collaboration agreement to evaluate combination regimen of two novel immunotherapies.http://news.bms.com/press-release/partnering-news/bristol-myers-squibb-and-incyte-enter-clinical-collaboration-agreement(accessed June 17, 2015) .
A phase 1/2 randomized, blinded, placebo controlled study of ipilimumab in combination with INCB024360 or placebo in subjects with unresectable or metastatic melanoma.https://www.clinicaltrials.gov/ct2/results?term=A+Phase+1%2F2+Randomized%2C+Blinded%2C+Placebo+Controlled+Study+of+Ipilimumab+in+Combination+With+INCB024360+or+Placebo+in+Subjects+With+Unresectable+or+Metastatic+Melanoma&Search=Search(accessed June 17, 2015) .
A phase 2 study of the IDO inhibitor INCB024360 versus tamoxifen for subjects with biochemical-recurrent-only EOC, PPC or FTC following complete remission with first-line chemotherapy.https://www.clinicaltrials.gov/ct2/results?term=A+Phase+2+Study+of+the+IDO+Inhibitor+INCB024360+Versus+Tamoxifen+for+Subjects+With+Biochemical-recurrent-only+EOC%2C+PPC+or+FTC+Following+Complete+Remission+With+First-line+Chemotherapy+&Search=Search(accessed June 17, 2015) .
Incyte announces clinical trial collaboration with Merck to evaluate combination of two novel immunotherapies.http://investor.incyte.com/phoenix.zhtml?c=69764&p=irol-newsArticle&ID=1897007(accessed June 17, 2015) .
Dolwick K. M., 1993, Mol. Pharmacol., 44, 911
Dominguez, C. L. A.; Toledo-Sherman, L. M.; Courtney, S. M.; Prime, M.; Mitchell, W.; Brown, C. J.; De Aguiar, P. C.; Johnson, P.Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof. WO2013016488, 2013.